Tumor uptake as a function of tumor mass: a mathematic model
- PMID: 3335916
Tumor uptake as a function of tumor mass: a mathematic model
Abstract
Inverse correlations of tumor uptake (u), measured in percent injected dose per gram, with tumor mass (m) are demonstrated for phospholipid vesicle, nonspecific and specific monoclonal antibody tracers. Correlation coefficients implied u = B mA in 11 different animal experiments. Experimental exponent (A) values lay in the range -0.28-0.64 with a mean of -0.43 while intercept (B) values varied from 3 to 18. Spherical and cylindrical tumor models implied exponents of -0.33 and -0.5, respectively. Comparison of three implantation sites of the human LS174T xenograft revealed a narrow range of exponents (-0.38- -0.46) indicating a consistent geometry for this tumor. Blood flow to the lesion site and inside its volume (as dictated by tumor size) are factors in tumor uptake. Our results indicate that biodistribution data should include the variation of tumor uptake with mass. For less than 10 g lesions, we predict that radiation absorbed dose will be highly dependent upon tumor size.
Similar articles
-
Pharmacokinetics, biodistribution, and gamma camera imaging of 111In-KC-4G3 murine monoclonal antibody in athymic nude mice with or without human tumor xenografts.Cancer Res. 1990 Sep 15;50(18):5954-61. Cancer Res. 1990. PMID: 2393864
-
Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice.Cancer Res. 1989 Jun 1;49(11):2884-9. Cancer Res. 1989. PMID: 2470499
-
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens.J Nucl Med. 1988 Feb;29(2):226-34. J Nucl Med. 1988. PMID: 3346734
-
Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.Cancer Res. 1990 Oct 1;50(19):6371-8. Cancer Res. 1990. PMID: 1698120
-
Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7130s-7136s. doi: 10.1158/1078-0432.CCR-1004-0006. Clin Cancer Res. 2005. PMID: 16203812
Cited by
-
Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours.Br J Cancer. 1989 Jan;59(1):135-41. doi: 10.1038/bjc.1989.27. Br J Cancer. 1989. PMID: 2788006 Free PMC article.
-
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Pharmacol Rev. 2016 Jul;68(3):701-87. doi: 10.1124/pr.115.012070. Pharmacol Rev. 2016. PMID: 27363439 Free PMC article. Review.
-
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.Cancer Biother Radiopharm. 2008 Aug;23(4):399-409. doi: 10.1089/cbr.2007.0457. Cancer Biother Radiopharm. 2008. PMID: 18771344 Free PMC article.
-
Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.Cancer Biother Radiopharm. 2017 Sep;32(7):258-265. doi: 10.1089/cbr.2017.2223. Cancer Biother Radiopharm. 2017. PMID: 28910150 Free PMC article. Clinical Trial.
-
Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry.Cancer Biother Radiopharm. 2015 Nov;30(9):369-79. doi: 10.1089/cbr.2014.1803. Cancer Biother Radiopharm. 2015. PMID: 26560193 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources